Macrocure Ltd. Reports Changes to Senior Management and the Board of Directors

PETACH TIKVA, Israel, Nov. 27, 2015 (GLOBE NEWSWIRE) -- Macrocure Ltd. ("Macrocure" or the "Company") (NASDAQ:MCUR), today announced that as the Company continues to explore potential strategic alternatives, Tomer Kariv, a current Director on the Company's Board and CEO & Founder of Pontifax, will become Chairman of the Board replacing David Ben-Ami, current Chairman of the Company's Board of Directors, who will remain a member of Macrocure's Board of Directors. Mark Page, Chief Financial Officer, will be stepping down from his position at Macrocure by February 2016 to pursue other opportunities. Shai Lankry, current VP Finance and former CFO of Macrocure, will be assuming Mark's responsibilities. Dr. Michael Molyneaux, Chief Medical Officer, will also step down from his position in December.

Nissim Machiach, President & Chief Executive Officer said, "On behalf of the Board, we would like to profoundly thank David, Mark and Mike for their leadership and contributions to Macrocure. Finally, we are grateful to Tomer for assuming the Chairman role and to David for his continuing Board participation while the Company continues to explore potential strategic alternatives. The Company is in process of selecting and appointing an outside advisory firm to assist with this review."

About Macrocure Ltd.

Macrocure Ltd. is a clinical-stage biotechnology company that until recently was focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds.

For more information, please visit:

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to financial results forecasts, commercial results, clinical trials and regulatory authorizations. Forward-looking statements are based on Macrocure's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, unexpected results of clinical trials, delays or denial in regulatory approval process or additional competition in the market, including those risks discussed under the heading "Risk Factors" in Macrocure's Annual Report on Form 20-F for the year ended December 31, 2014 filed with the Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this announcement and Macrocure undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

For Investors:
Shai Lankry
Macrocure Ltd.